Jinesh Gheeya, MD, PhD
@JineshGheeya
Followers
1K
Following
6K
Media
137
Statuses
3K
Thoracic medical oncologist @OSUCCC_James | clinical trialist | ICI and cell therapy | s/p @UCDavis @NIH @RWJMS @UTHIMRES
Ohio, USA
Joined August 2022
Asked @OpenAI to write a sonnet about recent advances in lung cancer treatment. It’s remarkably prescient. #lcsm @HemOncFellows
3
3
27
RT @christinemphmd: “Old does not = frail.” Dr. Carolyn Presley @CPresGeriOncMD discusses the design of the ACHIEVE study, emphasizing the….
0
12
0
RT @DAVAOnc: Early-stage lung cancer detection strategy! Dr.@LoganRoofMD of @OSUWexMed details the Lung Nodule Clinic model—>60 lung cance….
0
7
0
RT @KatsuakiMaehara: 1/3. 🫁 #Afatinib vs Chemotherapy with #Uncommon #EGFR Mutations: ACHILLES/TORG1834. ⭐️ Final OS analysis. #ASCO25.Abst….
0
30
0
RT @DrJNaidoo: #ASCO25 Developmental Therapeutics CSS🔥. Another presentation on timing of chemo-IO, this time a large observational study o….
0
19
0
RT @ozdogan_md: 💥 Landmark update by @stolaney1 in HER2+ metastatic breast cancer at #ASCO25!. 🎯 #destinybreast09 :.T-DXd + pertuzumab comb….
0
33
0
RT @IlanaSchlam: #ASCO2025 was filled with groundbreaking science. Feeling inspired and grateful to be part of this community. These are ju….
0
136
0
RT @StephenVLiu: Update from the Phase 2 PHAROS Study of encorafenib + binimetinib in #BRAF V600E NSCLC @JTOonline. As 1L therapy, RR 75%,….
0
32
0
RT @christine_lovly: Dr. Shun Lu presents Phase 3 Aumolertinib (EGFR TKI) vs. Aumolertinib + platinum chemo in pts with EGFRmt stage 4 #lun….
0
13
0
RT @AnaVManana: Impressive preliminary efficacy & safety of Zoldonrasib (RMC-9805) in KRAS G12D NSCLC .🔹MOA: oral RAS(ON) covalent, mutant….
0
29
0
RT @AnaVManana: 🔑 #LungCancer #ClinicalTrials at #AACR25 !.Zongertinib in pretreated HER2 mut. NSCLC: Beamion LUNG-1.🔹ORR 71% (7% CR) with….
0
31
0
RT @HerediaOncologo: Not all Lung adenocarcinomas (LUAD) respond the same. 📊Mucinous LUAD = 10% of cases, often KRAS+, TTF1–, PD-L1 low.Wor….
0
27
0
RT @KatsuakiMaehara: 🫁 Stage III NSCLC 🫁. 🫁 @ASCO Guideline Rapid Recommendation Update Clinical Insights
0
49
0
RT @isliquidbiopsy: 🚨 Can ctDNA Clearance Predict Response to Neoadjuvant Immunotherapy? 🧬🩸. Valenza et al., Annals of Oncology, 2025. 📊 S….
0
39
0
RT @herbloong: Happy to share our recent @ESMO_Open paper on the #safety and #feasibility of #outpatient administration of #tarlatamab as p….
0
28
0
RT @DrJNaidoo: Real-world outcomes of KRAS G12C & KRAS G12D+ NSCLC #LungCancer . - 298pts (G12C=216; G12D=82)🇦🇺.- G12D ⬆️ in never smokers….
0
12
0
RT @HHorinouchi: 🔥@trendscancer🆙.✅Turning cold into hot: emerging strategies to fire up the tumor microenvironment.🎯Summary of the intrinsi….
0
12
0
RT @ChristianRolfo: 🚨We are hiring Medical Oncologists at @OhioStateMedOnc ! . Check the QR code below for the available positions! 3 pat….
0
15
0
RT @emilylasse: I’m so excited to say my 1st first-author paper has been published! Thank you to everyone who has helped me get this to the….
0
15
0